Ascentage Pharma of Shanghai out-licensed rights for a small molecule inhibitor of Bcl-2 proteins to treat age-related diseases of the eye to Unity Biotech, a Bay Area company. As an upfront payment, Ascentage will receive shares in Unity Biotech. It will also receive cash milestone payments and royalties based on clinical and commercial milestones. Earlier this week, Ascentage announced a collaboration with MD Anderson Cancer Center to conduct US clinical trials of five cancer drug candidates.
Source: China Biotoday
